ArticleFrontiers in public health2023
Polypharmacy, chronic kidney disease, and mortality among older adults: A prospective study of National Health and nutrition examination survey, 1999-2018.
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Deprescribing for Comorbidities in Patients with Cancer - a Systematic Review.Current oncology reports · 2026Pooled it
- Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors.Renal failure · 2026Observational
- Recommendations for the management of frailty in chronic kidney disease: a consensus report.Nature reviews. Nephrology · 2026Review
- Assessing Associations of Three Types of Higher-Risk Medication Use and Mortality in Older Adults.Journal of the American Geriatrics Society · 2026Article
- CKD as an independent driver of polypharmacy.Clinical kidney journal · 2026Article
- Dosage adjustments in renal impairment among medical ward patients: ChatGPT® and DeepSeek® models' effectiveness in assessing those adjustments.Exploratory research in clinical and social pharmacy · 2026Article
- Prevalence and determinants of cardiometabolic comorbidities among people living with HIV receiving antiretroviral therapy at Zewditu Memorial Hospital: evidence from Ethiopia's longest serving AIDS clinic.BMC infectious diseases · 2026Article
- Artificial intelligence-driven risk prediction of polypharmacy in older adults: current advances, clinical applications, and future perspectives.Frontiers in public health · 2026Review
- Article
- Polypharmacy and its association with dementia, Parkinson's disease, and mortality risk in UK adults: a multistate modeling approach.GeroScience · 2025Article
- Management of Elderly Patients with Chronic Kidney Disease.Yonsei medical journal · 2025Review
- Article
- Magnitude of multiple drug use and determinants of vulnerability among chronic kidney disease inpatients in Ethiopia: a multi-center study.BMC nephrology · 2024Article
- Cardiac and Renal Comorbidities in Aging People Living With HIV.Circulation research · 2024Review
- Association between polypharmacy and chronic kidney disease among community-dwelling older people: a longitudinal study in southern China.BMC nephrology · 2024Article
- Polypharmacy Is Associated with Sociodemographic Factors and Socioeconomic Status in United States Adults.Pharmacy (Basel, Switzerland) · 2024Article
- Prevalence and trends of polypharmacy in U.S. adults, 1999-2018.Global health research and policy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Polypharmacy might contribute to a range of adverse outcomes, which could get worse in the elderly with chronic kidney disease (CKD). Evidence on polypharmacy, CKD, and mortality is scarce. We aimed to investigate the prospective association between polypharmacy, CKD and all-cause and cause-specific mortality in adults aged ≥65 years. Methods: A total of 13,513 adults from the National Health and Nutrition Examination Surveys were included, following up from 1999 to 2018 until December 31, 2019. The simultaneous use of ≥5 medications by one individual was defined as polypharmacy. Survey-weighted Cox proportional hazard models were used to estimate the hazard ratio (HRs) for mortality from all-cause, cardiovascular diseases (CVD), and cancer after adjusting for potential confounding factors. Results: Among the elderly with CKD, we identified 3,825 total deaths (1,325 CVD and 714 cancer) during a median follow-up of 7.7 years. Participants with polypharmacy had a 27% (HR = 1.27 [1.15, 1.39]) and 39% (HR = 1.39 [1.19, 1.62]) higher risk of all-cause and CVD mortality, respectively, but not for cancer mortality. Compared with the elderly with no polypharmacy and no CKD, the corresponding HRs (95%CIs) for all-cause mortality were 1.04 (0.96, 1.14) for those with no polypharmacy but CKD, 1.24 (1.11, 1.39) for with polypharmacy but no CKD, and 1.34 (1.21, 1.49) for those with both polypharmacy and CKD. A similar pattern was detected for CVD mortality. Discussion: Polypharmacy was associated with elevated risks of all-cause and CVD mortality among the elderly CKD patients. More evidence-based approaches should be promoted for the appropriate deprescribing in the older adults with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.